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Abstract 
Background: The aims of this study were to prospectively assess the prevalence of sustained (lasting more than 30 s) 
new‑onset supraventricular arrhythmia (NOSVA) during septic shock, identify the associated factors (including septic 
myocardial dysfunction), and evaluate its impact on hemodynamics and prognosis.
Methods: Patients with a diagnosis of septic shock were screened in a medical intensive care unit of a tertiary hospi‑
tal center in France with a continuous 12‑lead EKG for the occurrence of NOSVA. Biological and clinical data (including 
septic myocardial dysfunction characterized by echocardiography) were collected. We also assessed the hemody‑
namic tolerance and prognosis of NOSVA.
Results: Among the 71 septic shock episodes assessed during the study, NOSVA occurred in 30 [prevalence of 42 %, 
95 % confidence interval (CI) 30–53 %]. Among all recorded factors, only renal failure (as assessed by renal SOFA score 
at day 1) was associated with NOSVA and this difference persisted by multivariable analysis (odds ratio of 1.29, 95 % CI 
1.03–1.62, p = 0.03). There was a significant increase in norepinephrine dosage during the first hour after SVA onset. 
NOSVA was associated with longer catecholamine use during septic shock as compared with patients in sinus rhythm, 
whereas ICU mortality was identical between groups.
Conclusions: We found a high prevalence of sustained NOSVA during septic shock. NOSVA was not related to septic 
myocardial dysfunction, but rather to acute renal failure, raising the hypothesis of an acute renocardiac syndrome.
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Background
Supraventricular arrhythmia (SVA) is the most common 
cardiac rhythm disturbance occurring in intensive care 
unit (ICU) patients [1]. Sepsis is frequently associated 
with new-onset SVA (NOSVA), which has been reported 
in 6  % of patients with severe sepsis [2] and in 46  % of 
those with septic shock [3]. Data evaluating risk factors 
for NOSVA during septic shock are scarce [2, 4].
Septic myocardial dysfunction is characterized by 
an acute, reversible depression of left ventricle (LV) 
contractility with normal or low filling pressures [5]. Its 
mechanisms are not fully understood, though circulating 
cytokines or cellular respiration alteration resulting from 
mitochondrial dysfunction may play a crucial role [6]. 
Septic cardiomyopathy may also involve diastolic dys-
function [7] and right ventricle dysfunction [8]. Whether 
septic cardiomyopathy may constitute an arrythmogenic 
condition is unknown to date. In addition, whether ino-
tropic drugs used to correct LV systolic dysfunction in 
septic shock patients [8] may increase the risk of NOSVA 
remains unclear.
SVA has been associated with increased morbid-
ity related to circulatory compromise, cardio-embolic 
events or hemorrhagic complications of anticoagulant 
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treatments. Little is known about the prognostic impact 
of NOSVA in the context of septic shock [2].
The aim of our study was to prospectively assess the 
prevalence of NOSVA during septic shock, to identify the 
associated factors (including the role of septic myocardial 
dysfunction), and to evaluate its impact on hemodynam-
ics and outcome of patients.
Patients and methods
Patients
Patients who met septic shock criteria (as defined accord-
ing to the ACCP/SCCM Consensus Conference [9]) were 
prospectively included at the medical ICU of Henri Mon-
dor University Hospital (Créteil, France) between Octo-
ber 2011 and December 2012. Non-inclusion criteria 
were cardiac surgery within the preceding month, chronic 
heart failure (defined by a baseline left ventricular ejec-
tion fraction below 45 %) or a history of persistent SVA. 
The study was approved by the institutional ethics com-
mittee (Comité de Protection de Personnes Ile de France 
IX) as a component of standard care and patient’s consent 
was waived. Written and oral information about the study 
was given to the families. Patient’s severity was evaluated 
by the McCabe and Jackson score for underlying diseases 
[10], the SAPS II score for acute illness at ICU admission 
[11] and the SOFA (sequential organ failure assessment) 
score for organ dysfunction during septic shock [12]. 
Chronic renal failure was defined as a glomerular filtra-
tion rate below 30  ml/min/1.73  m2 according to MDRD 
formula [13]. Acute renal failure and other organ failures 
were defined using the SOFA score [12]. Acute respiratory 
distress syndrome (ARDS) was defined according to the 
Berlin criteria [14]. Blood concentration of thyroid stimu-
lating hormone, NT-pro BNP and cardiac troponin T were 
assessed using an immuno-assay on a COBAS 6000 ana-
lyzer (Roche Diagnostics, Boulogne-Billancourt, France). 
Follow-up for the study was at least until ICU discharge.
NOSVA
All patients were continuously monitored with a recon-
structed 12-lead EKG (using a continuous 6-lead cardiac 
monitoring, Dräger Infinity® Acute Care System, Antony, 
France). EKG data were automatically recorded, digitally 
stored and checked daily for occurrence of NOSVA dur-
ing the entire course of septic shock. SVA episodes last-
ing more than 30  s were assessed by two cardiologists 
(any discrepancy being solved by consensus) and classi-
fied as atrial fibrillation, atrial flutter or atypical flutter, 
using standard definitions [15].
Septic myocardial dysfunction
To evaluate cardiac function, we used transthoracic 
echocardiography (TTE) or multiplane transesophageal 
echocardiography (TEE), when TTE did not allow accu-
rate measurements because of poor acoustic windows. 
Echocardiograms were performed by trained operators 
(competence in advanced critical care echocardiog-
raphy) [16] using an iE33 system (Philips Ultrasound, 
Bothell, WA, USA) with a standard procedure [17]. 
Briefly, the following echocardiographic views were 
examined: four-chamber and two-chamber long-axis 
views to assess left ventricle (LV) ejection fraction (com-
puted from LV volumes using the bi-plane Simpson 
method [18] when image quality was good, or visually 
estimated when poor image quality did not allow suffi-
cient identification of the endocardium [19]), right and 
left atrium size [18], right ventricle size (a dilated RV 
was defined by an end-diastolic RV/LV area ratio >0.6) 
[20]), right ventricle function (using the tricuspid annu-
lar plane systolic excursion and tissue Doppler peak sys-
tolic wave at the tricuspid valve annulus [21]); long-axis 
M-mode view of the superior (TEE) or inferior (TTE) 
vena cava to assess their respiratory variability [22]; and 
the presence of pericardial effusion. Pulsed-wave Dop-
pler aortic flow was obtained at the level of the aortic 
annulus and the velocity–time integral was automati-
cally processed by tracing the envelope of aortic flow 
for cardiac index calculation. Echocardiographic images 
were digitally stored, and a computer-assisted evalua-
tion was performed off-line by two trained operators. 
Septic cardiac dysfunction was defined as an LVEF 
<45 % or the need for an inotrope infusion in order to 
achieve an LVEF ≥45 %.
Statistical analysis
The data were analyzed using SPSS Base 13.0 (SPSS 
Inc, Chicago, IL, USA) and R 2.15.2 (The R Founda-
tion for Statistical Computing, Vienna, Austria) statisti-
cal software packages. Continuous data were expressed 
as median [25th–75th percentiles], unless otherwise 
specified and were compared using the Mann–Whit-
ney test for independent samples and the Friedman test 
for related samples. Categorical variables, expressed 
as percentages, were evaluated using the Chi-square 
test or Fisher exact test. To evaluate independent fac-
tors associated with NOSVA (time-dependent variable), 
significant or marginally significant univariate risk fac-
tors (p < 0.10) recorded prior or at the time of the first 
episode of NOSVA, were examined using backward 
stepwise multivariate Cox proportional-hazards regres-
sion model; septic myocardial dysfunction and patient 
severity as assessed by SAPS II score at ICU admission 
were also included in the model; thus, the five variables 
included in the model were SAPS II score at ICU admis-
sion, age, septic myocardial dysfunction, renal and non-
renal SOFA scores at day 1 of septic shock. Coefficients 
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were computed by the method of maximum likelihood. 




Eighty-six patients were admitted in our unit with a diag-
nosis of septic shock during the study period. Among 
them, 21 patients were excluded because of cardiac sur-
gery within the preceding month (n = 8), chronic heart 
failure (n  =  6), history of permanent atrial fibrillation 
(n = 4) or logistic difficulties impeding proper data col-
lection (n = 3). Thus, a total of 65 patients were included 
in the study, with 71 episodes of septic shock (six patients 
exhibited two distinct episodes of septic shock during 
the study period). Baseline characteristics of included 
patients are displayed in Table 1. SAPS II at ICU admis-
sion was 51 [39–68], and SOFA score at onset of septic 
shock was 10 [7–14]. NOSVA occurred during 30 septic 
shock episodes (in 27 patients), defining a prevalence of 
42 % (95 % CI 30–54 %). In the six patients with two dis-
tinct episodes of septic shock (more than 1 week apart), 
three experienced a paroxysmal NOSVA during the first 
episode with a relapse during the second episode, one 
experienced NOSVA during the first episode only, and 
two remained in sinus rhythm during both episodes. 
NOSVA subtypes were atrial fibrillation (n = 23), atypi-
cal flutter (n = 4) and atrial flutter (n = 3). The median 
time from septic shock onset to NOSVA was 2 [1–4] 
days, with 15 (50.0 %) episodes occurring on the first day 
of septic shock. NOSVA occurred only once during 19 
septic shock episodes and occurred two or more times 
during 11 septic shock episodes. The median cumulative 
length of NOSVA was 19.5 [3–57] h.
Factors associated with NOSVA occurrence
There was no significant difference in baseline character-
istics between patients with or without NOSVA, includ-
ing cardiovascular risk factors, cardiac medications, 
chronic renal failure, thyroid dysfunction, and SAPS II 
score at ICU admission (Table 1). Organ dysfunction and 
treatments administered during septic shock according to 
the occurrence of NOSVA are displayed in Table 2. Renal 
SOFA score at day 1 of septic shock was significantly 
higher in patients with NOSVA. Among the 11 patients 
with a NOSVA episode who needed dialysis during 
shock, arrhythmia occurred before dialysis initiation in 
six patients. Other organ dysfunctions (neurological, car-
diovascular, hematological, respiratory, coagulation and 
hepatic) had similar rates between groups. Daily fluid bal-
ance was not associated with the occurrence of NOSVA. 
Maximal doses of catecholamines infused did not dif-
fer between patients with NOSVA and others. Biological 
data, including blood potassium, thyroid stimulating hor-
mone, cardiac Troponin T and NT-pro-BNP levels were 
similar between groups. Respiratory variables and the use 
of superior vena cava central line were similar between 
groups. Overall, steroid use for septic shock was signifi-
cantly higher among patients with NOSVA as compared 
to those without, but this difference disappeared when 
considering only steroids administered before SVA onset.
Temperature and biological data at the time of the first 
occurrence of SVA are displayed in Table 3. Overall, these 
variables were within the normal range in the majority of 
patients experiencing the first SVA episode, except for 
elevated serum urea and creatinine which were common 
in this group.
Table  4 shows echocardiographic parameters in 
patients with and without NOSVA. As expected, 
Table 1 Patients’ baseline characteristics, according to the 
occurrence of new-onset supraventricular arrhythmia dur-
ing at least one septic shock episode
Data are n (%) or median [25th–75th percentile] unless otherwise specified
Chronic renal failure was defined as a glomerular filtration rate below 30 ml/
min/1.73 m2  according to simplified MDRD formula [13]
NOSVA new-onset supraventricular arrhythmia, PM pacemaker, ICD intra-cardiac 
defibrillator, SAPS Simplified Acute Physiologic Score, ICU intensive care unit, 
LVEF left ventricular ejection fraction
NOSVA during septic shock episode p value
Never (n = 38) Ever (n = 27)
Age, years 55.5 [48.5–68.5] 66 [56–75.0] 0.071
Weight, kg 73.0 [57.0–85.0] 72.0 [64.0–89.0] 0.464
Height, cm 171 [164–178] 170.0 [162.55–173.5] 0.468
Female sex 15 (39.5) 14 (51.9) 0.323
History of cardiac  
disease
15 (39.5) 6 (22.2) 0.143
 Coronary artery  
disease
7 (18.4) 4 (14.8) 0.751
 Paroxysmal SVA 3 (7.9) 5 (18.5) 0.260
 Valvular heart disease 3 (7.9) 1 (3.7) 0.636
 PM or ICD 2 (5.3) 1 (3.7) >0.99
Chronic renal failure 3 (8.1) 2 (7.4) >0.99
Chronic dialysis 2 (5.3) 2 (7.4) >0.99
History of stroke 3 (7.9) 3 (11.1) 0.686
History of thyroid  
dysfunction
2 (5.3) 1 (3.7) >0.99
Diabetes 8 (21.1) 5 (18.5) 0.801
Smoker 11 (28.9) 8 (29.6) 0.952
History of dyslipidemia 5 (13.2) 5 (18.5) 0.729
History of hypertension 15 (39.5) 8 (29.6) 0.413
Betablocker use 13 (34.2) 7 (25.9) 0.589
Amiodarone use 4 (10.5) 2 (7.4) >0.99
McCabe score 1.0 [0.0–2.0] 1.0 [0.0–2.0] 0.321
SAPS II score at ICU 
admission
48.5 [33.2–62.2] 56 [40–71] 0.136
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Table 2 Organ dysfunction, biological data and treatments during septic shock according to supraventricular arrhythmia 
occurrence
Data are n (%) or median [25th–75th percentile] unless otherwise specified
SVA supraventricular arrhythmia, SOFA sepsis-related organ failure assessment, PEEP positive end-expiratory pressure, ARDS acute respiratory distress syndrome
a Only patients receiving the drug during septic shock were considered
Sinus rhythm (n = 41) SVA (n = 30) p
SOFA day 1
 Global (0–24) 10.0 [7.0–12.5] 10 [8–16] 0.369
 Neurological (0–4) 1.0 [0.0–4.0] 1.0 [0.0–4.0] 0.869
 Respiratory (0–4) 2.0 [0.0–4.0] 2.0 [0.8–3.0] 0.976
 Cardiovascular (0–4) 4.0 [4.0–4.0] 4.0 [4.0–4.0] 0.709
 Renal (0–4) 1.0 [0.0–2.5] 2.0 [1.0–4.0] 0.034
 Coagulation (0–4) 0.0 [0.0–1.5] 1.0 [0.0–2.0] 0.573
 Hepatic (0–4) 0.0 [0.0–2.0] 0.0 [0.0–1.25] 0.875
Day 1 blood gases
 pH 7.33 [7.21–7.41] 7.32 [7.24–7.40] 0.802
 PCO2, mmHg 37.0 [29.0–44.5] 36.0 [30.7–47.5] 0.692
 PO2, mmHg 123.0 [84.5–185.5] 102.0 [76.0–215.2] 0.802
 Bicarbonates, mmol/L 19.0 [15.9–25.2] 20.5 [17.0–25.0] 0.518
 Lactate, mmol/L 2.90 [1.43–4.30] 2.10 [1.40–3.60] 0.514
 FIO2, % 100 [55–100] 100 [70–100] 0.910
 PEEP, cmH2O 5 [5] 5 [5] 0.759
Thyroid stimulating hormone, µUI/L 0.94 [0.35–3.12] 1.04 [0.34–2.26] 0.694
Cardiac Troponin peak between day 1 and day 3, ng/L 44 [12.5–295] 157.5 [22.7–545.8] 0.222
NT proBNP peak between day 1 and day 3, pg/mL 8092 [2424–32,410] 15,522 [5987–46209] 0.229
Minimal potassium level during septic shock, mmol/L 3.3 [2.8–3.7] 3.2 [2.9–3.4] 0.571
Maximal potassium level during septic shock, mmol/L 4.6 [4.3–5.2] 4.5 [4.2–5.1] 0.771
Hemodynamic treatments
 Cumulative fluid balance during shock, mL 5358 [2401–9965] 4233 [3241–9682] 0.979
 Daily fluid balance during shock, mL/day 2285 [1554–3825] 1387 [1080–1859] 0.106
 Dobutamine use during shock 8.0 (19.5) 5 (16.7) 0.759
 Dobutamine maximal dose, µg/kg/mina 5.0 [5.0–13.8] 10.0 [5.0–12.5] 0.622
 Dobutamine maximal dose, µg/kg/min, mean (SD)a 7.8 (4.9) 9.0 (4.2)
 Norepinephrine use during shock 40 (97.6) 29 (96.7) >0.99
 Norepinephrine maximal dose, mg/ha 2.9 [1.2–8.0] 3.3 [2.0–10.0] 0.210
 Norepinephrine maximal dose, mg/h, mean (SD)a 5.1 (5.5) 6.7 (6.4)
 Epinephrine use during shock 3 (7.3) 3 (10.0) 0.692
 Dual catecholamine use during shock 10 (24.4) 6 (20.0) 0.662
 Length of catecholamine use during shock, days 3 [2–5] 4 [3–7] 0.035
 Length of vasopressor use during shock, days 3 [2–5] 4 [3–7.0] 0.021
Respiratory treatments
 Invasive mechanical ventilation 33 (80.5) 27 (90.0) 0.335
 Mild ARDS 7 (17.9) 7 (24.1) 0.532
 Moderate to severe ARDS 17 (41.5) 11 (36.7) 0.683
Other treatments
 Dialysis during shock 7 (17.1) 11 (36.7) 0.061
 Steroid use during shock 25 (61.0) 25 (83.3) 0.041
 Steroid use before SVA onset 25 (61.0) 14 (46.7) 0.231
Superior vena cava central line in place during shock 13 (31.7) 10 (33.3) 0.885
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echocardiograms were performed less often in sinus 
rhythm in the NOSVA group. Cardiac chamber sizes, 
presence of pericardial effusion as well as median LVEF 
were similar between the two groups. The presence 
of septic myocardial dysfunction was similar between 
groups (p = 0.303 and p = 0.329 for Chi-square test and 
log-rank test, respectively).
In the Cox proportional-hazards regression analy-
sis adjusted for septic myocardial dysfunction, SAPS II 
score and renal and non-renal SOFA scores at day 1 of 
septic shock, the only factor significantly associated with 
NOSVA was the renal SOFA score at day 1 of septic 
shock (hazard ratio of 1.29, 95 % CI 1.03–1.62, p = 0.03; 
Table 5).
Treatment of NOSVA
A treatment for cardioversion was administered in 21 
of 30 episodes of NOSVA, including magnesium sul-
fate (n = 6), amiodarone (n = 19), and/or electric shock 
(n =  3). Cardioversion was effective in 18 (86  %) cases. 
Curative anticoagulant treatment with heparin was used 
in eight (27 %) patients with NOSVA; in the other cases, 
the attending physician considered that the benefit/risk 
ratio of curative anticoagulation was unfavorable. No 
stroke was diagnosed among patients with NOSVA up to 
ICU discharge.
Outcome of NOSVA
Table 6 shows hemodynamic changes induced by the first 
recorded episode of NOSVA. There was a trend towards 
Table 3 Body temperature and  biological variables strati-
fied according to  their reference limits, at  time of  first 
occurrence of  supraventricular arrhythmia during  septic 
shock
Data are n (%) or median [25th–75th percentile] unless otherwise specified
SVA supraventricular arrhythmia
Variables SVA (n = 30)
Temperature, °C 37.3 [36.0–38.2]
Temperature >38.3 °C 7 (21.9)
Temperature <36.0 °C 4 (12.5)
Potassium level, mmol/L 3.7 [3.4–4.2]
Potassium level <3.5 mmol/L 8 (25.0)
Potassium level >5 mmol/L 2 (6.3)
Glycemia, mmol/L 6.5 [5.5–8.4]
Glycemia <4 mmol/L 3 (9.7)
Glycemia >10 mmol/L 6 (19.4)
pH 7.39 [7.29–7.44]
pH <7.38 14 (43.8)
PaCO2, mmHg 34.0 [30.0–40.2]
PaO2, mmHg 100 [85–164]
PaO2 <60 mmHg 1 (3.1 %)
SaO2 (%) 98 [96–100]
Bicarbonates, mmol/L 21.2 [18.0–24.8]
Lactates, mmol/L 1.6 [1.3–3.3]
Serum creatinine, µmol/L 157 [90–272]
Serum creatinine >130 µmol/L 20 (62.5)
Serum urea, mmol/L 12.9 [7.9–21.1]
Serum urea >7 mmol/L 26 (81.3)
PaO2/FiO2 ratio 228 [175–340]
Table 4 Echocardiographic data during septic shock
Data are n (%) or median [25th–75th percentile]
SVA supraventricular arrhythmia; E/e′ ratio ratio of transmitral Doppler early (E) filling velocity to tissue Doppler early diastolic mitral annular velocity; RA right atria; LA 
left atria; LV left ventricle; RV right ventricle, RV dilatation was defined as end-diastolic area ratio >0.6; TAPSE tricuspid annular plane systolic excursion
a One patient had internal pacing
b Two patients were excluded from this analysis because of a poor echogenicity
Sinus rhythm (n = 41) SVA (n = 30) p
Echocardiogram on sinus rhythm 40 (97.6)a 23 (76.7) 0.006
Echocardiogram under inotropes 2 (4.9) 4 (13.3) 0.233
LVEF, % 60 [44–60] 59 [44–60] 0.587
Septic myocardial dysfunction (n = 69)b 11 (28.2) 12 (40.0) 0.303
Cardiac index, L/min/m2 2.8 [2.2–3.6] 3.4 [2.5–3.8] 0.131
E/e′ ratio 8.5 [6.9–11.5] 8.3 [5.3–10.8] 0.547
RV/LV ratio 0.6 [0.4–0.7] 0.5 [0.4–0.7] 0.818
RV dilatation 20 (51.3) 12 (42.9) 0.496
RA size, cm2 12.1 [11.0–17.5] 15.6 [11.0–19.7] 0.422
LA size, cm2 17.0 [14.2–21.0] 18.0 [14.0–19.5] 0.879
TAPSE, mm 20.0 [17.0–22.0] 17.0 [13.8–25.0] 0.150
Tricuspid tissue Doppler s’ wave, cm/s 13 [10–14] 13 [8–15] 0.812
Pericardial effusion 3 (7.3) 4 (13.3) 0.446
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a decrease in mean, systolic and pulse arterial pressure 
despite a significant increase in norepinephrine dosage 
during the first hour after SVA onset. NOSVA was asso-
ciated with longer catecholamine use and longer vaso-
pressor use during septic shock (Table 2). ICU mortality 
was identical between patients with NOSVA and those 
without [16 (42.1 %) vs. 13 (48.1 %), p = 0.63], whereas 
there was a trend towards prolonged ICU length of stay 
in ICU survivors in the former group (16.0 [10.5–32.0] 
days vs. 8.5 [4.0–24.5] days, p = 0.08).
Sensitivity analyses
When repeating the analyses while considering only the 
first episode of septic shock in patients with multiple 
episodes, we found concordant results: (1) in the Cox 
proportional-hazards regression analysis, the only fac-
tor associated with NOSVA was the renal SOFA score at 
day 1 of septic shock [hazard ratio of 1.26 (95 % CI 0.99–
1.60), with a marginally significant p value (p  =  0.06]; 
(2) NOSVA was associated with longer catecholamine 
use (4 [3–7] vs. 3 [2–6], p = 0.049), and vasopressor use 
(4 [3–7] vs. 3 [2–5], p =  0.03) during septic shock, and 
a trend towards longer ICU length of stay in survivors 
(16.0 [10.0–32.0] days vs. 8.5 [4.0–24.0] days, p = 0.067).
Discussion
We report a high prevalence of NOSVA (42 %; 95 % CI 
[30–54 %]) during septic shock. NOSVA was not associ-
ated with septic myocardial dysfunction, but with renal 
failure by multivariable analysis. Patients with NOSVA 
exhibited longer durations of shock and a trend towards 
longer ICU stay.
The prevalence of NOSVA in our study is higher than 
reported in the general ICU population [1, 2, 23], but 
comparable to the 46  % atrial fibrillation rate reported 
by Meierhenrich et  al. [3] in a cohort of patients with 
septic shock. The higher prevalence of SVA in septic 
shock patients might be related to their higher severity 
of illness. The use of inotropes in septic shock patients is 
unlikely to fully explain such a difference, since many of 
our patients presented NOSVA before initiating catecho-
lamine support.
We were unable to demonstrate an association between 
the occurrence of NOSVA and septic myocardial dys-
function, as assessed by LVEF. Several explanations are 
possible. First, LVEF may not be the ideal criterion to 
assess septic cardiomyopathy, notably because of its load-
dependency. However, evaluation of cardiac function in 
our patients was done after fluid loading and while receiv-
ing vasoconstrictors. Whether echocardiographic param-
eters less dependent on afterload, such as speckle tracking 
derived strain-rate, may better characterize septic cardio-
myopathy warrants further research. Second, the mecha-
nisms of septic myocardial dysfunction and substrates/
triggers of SVA may differ. Septic cardiomyopathy mainly 
affects heart ventricles, with depressed contractility and 
Table 5 Factors associated with new-onset supraventricu-
lar arrhythmia occurrence by Cox analysis
SAPS Simplified Acute Physiologic Score; SOFA sepsis-related organ failure 
assessment; ICU intensive care unit; I/NR included, but not retained in the final 
model
Variable Hazard ratio (95 % CI), p value
Univariate Multivariable
SAPS II score at ICU 
admission
1.02 (1.00–1.03), p = 0.05 I/NR
Age 1.02 (0.99–1.05), p = 0.23 I/NR
Septic myocardial 
dysfunction
1.40 (0.68–2.92), p = 0.36 I/NR
Renal SOFA 1.28 (1.02–1.60), p = 0.03 1.29 (1.03 1.62), p = 0.03
Non‑renal SOFA 0.99 (0.90–1.11), p = 0.97 I/NR
Table 6 Hemodynamic data immediately before and during the first hour of the first episode of supraventricular arrhyth-
mia
Data are n (%) or median [25th–75th percentile] unless otherwise specified
SVA supraventricular arrhythmia
a Only patients receiving the drug before or after SVA onset were considered
Before SVA onset (n = 30) After SVA onset (n = 30) p
Systolic arterial pressure, mmHg 114 [97–127] 97 [86–118] 0.076
Diastolic arterial pressure, mmHg 58 [51–63] 58 [47–64] 0.513
Mean arterial pressure, mmHg 77.0 [70.0–87.0] 73.0 [58.5–80.5] 0.056
Arterial pulse pressure, mmHg 54 [39–70] 42 [31–57] 0.081
Heart rate, beats/min 99 [87–118] 140 [123–165] <0.001
Dobutamine dose, µg/kg/mina 7.5 [5.0–10.0] 7.5 [5.0–10.0] >0.99
Norepinephrine dose, mg/ha 1.7 [0.3–3.0] 1.8 [0.5–4.5] 0.010
Epinephrine dose, mg/ha 1.3 [0.5–2.0] 1.5 [0.0–3.0] 0.655
Page 7 of 8Seemann et al. Ann. Intensive Care  (2015) 5:27 
low or normal filling pressures [6], whereas SVA is an 
atrial disorder that is mainly influenced by atrial pressure 
and autonomous nervous system tone. Cardiac biomark-
ers (B-type natriuretic peptides and troponins), which are 
mainly released from the ventricular myocytes and mostly 
influenced by left ventricle function and mass, were not 
significantly associated with SVA in our series despite a 
trend towards higher values in the NOSVA group.
We found an association between NOSVA and renal 
failure by univariate and multivariable analysis. Patients 
with NOSVA exhibited higher values of serum urea and 
creatinine, and a higher renal SOFA score as compared 
to patients in sinus rhythm, whereas the prevalence of 
chronic renal failure and chronic dialysis was similar 
between groups. Cardiorenal syndrome (CRS) is a com-
plex pathophysiological disorder of the heart and kidneys 
in which acute or chronic dysfunction in one organ may 
induce acute or chronic dysfunction in the other organ 
[24]. The association we observed between acute renal 
failure and NOSVA may correspond to either a type 1 
CRS (acute cardiorenal syndrome, i.e., an acute dete-
rioration in cardiac function that leads to acute kidney 
injury), a type 3 CRS (acute renocardiac syndrome, i.e., 
an acute kidney injury that leads to acute cardiac injury), 
or a type 5 CRS (secondary cardiorenal syndrome, i.e., a 
systemic disorder causing cardiac and renal dysfunction) 
[25, 26]. Hemodynamic alteration during SVA episodes 
might have impeded renal perfusion, thus leading to an 
acute cardiorenal syndrome. However, the renal SOFA 
score was significantly different between the NOSVA 
group and the sinus rhythm group from the very start of 
septic shock (day 1), favoring the hypothesis of an acute 
renocardiac syndrome. The mechanisms underlying 
acute renocardiac syndrome are not clearly understood, 
but may involve direct (e.g., cytokines, sympathetic tonus 
and renin–angiotensin–aldosterone system) or indirect 
(e.g., fluid and electrolyte imbalances) effects of acute 
kidney injury on the heart [27, 28]. However, in our 
study, the potential role of dyskalemia and fluid balance 
on the occurrence of NOSVA did not seem pivotal. Fur-
ther studies are needed to better scrutinize the spectrum 
of acute renocardiac syndrome in septic shock patients.
As expected, the occurrence of NOSVA during septic 
shock was associated with a poor acute hemodynamic 
tolerance, with a fall in arterial pressure and increased 
doses of catecholamines. Indeed, the loss of auricular 
systole and tachycardia-related shortening of ventricular 
diastole may both contribute to ventricular filling impair-
ment. NOSVA was also associated with longer use of 
drugs and vasopressors, and a trend towards longer ICU 
stay. Whether NOSVA is a direct cause of prolonged 
catecholamine use and longer ICU stay or merely an 
indicator of severity of illness remains to be determined. 
The absence of clinical ischemic stroke in our study 
despite a low curative anticoagulation rate underscores 
the need to weight the benefit/risk ratio of this treatment 
for each patient with NOSVA in the ICU setting.
Our study has several limitations. First, the study power 
was limited by the inclusion of only 71 episodes of septic 
shock. We cannot formally exclude a possible relationship 
between septic myocardial dysfunction and NOSVA in a 
larger sample size. In view of the 30 events observed, we 
did not strictly follow the classical rule of a minimum of 
10 outcome events per predictor variable in the multivari-
able analysis [29], but our analysis fulfilled the minimum 
of 5 events per predictor variable proposed by recent sim-
ulation studies [30]. Second, we included some patients 
with multiple septic shock episodes (more than 1  week 
apart). Our sensitivity analysis considering only the first 
episode yielded nearly similar results despite a reduced 
power. However, we cannot exclude a role for personal 
susceptibility in the occurrence of NOSVA. Third, we 
could not perform consecutive echocardiograms during 
sinus rhythm and at the onset of SVA to better scrutinize 
hemodynamic changes induced by SVA.
Conclusions
In conclusion, our study showed that sustained NOSVA 
is frequent during septic shock, poorly tolerated, and is 
associated with longer catecholamine use. Renal failure, 
but not myocardial dysfunction, was significantly asso-
ciated with occurrence of NOSVA  during septic shock, 
raising the hypothesis of an acute renocardiac syndrome.
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